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To the Editor:
A large number of research studies are currently 
collecting data about the whole range of short- and 
long-term health effects associated with SARS- 
-CoV-2 infection. Long COVID-19, post-COVID-19 also 
known as Long-haul COVID-19 is the current name 
being given to the long-term sequelae (persistent 
symptoms experienced longer than 6 weeks) of 
SARS-CoV-2 infection.  An estimated 10% of patients 
with COVID develop Long-haul COVID-19 symptoms 
[1]. Initial reports suggest that post viral fatigue (PVF) 
and Post viral fatigue syndrome (PVFS) are the most 
common long term issues in individuals infected with 
SARS-CoV-2. The severity and duration of the acute 
viral infection are strong risk factors for the develop-
ment of fatigue syndromes. According to an Australian 
research group, approximately 12% of 253 subjects 
developed a Post Viral Syndrome that involved fatigue, 
cognitive dysfunction, mood disturbance and muscu-
loskeletal pain [2].
Postinfectious syndromes including those seen 
with persistent symptoms after COVID-19, often 
share a common symptom phenotype, that is either 
self-limiting or has features that are very similar to 
myalgic encephalomyelitis/chronic fatigue syndrome 
(ME/CFS) [1, 3].  Recently, there have also been re-
ports about a high frequency of patient-reported Long-
haul-COVID-19 symptoms that as well as fatigue include 
cognitive difficulties (problems with short term/working 
memory, concentration, information processing), pain, 
orthostatic intolerance (problems in remaining upright, 
feeling dizzy), anxiety/depression, sleep and autonomic 
disturbances [4]. One symptom that is considered to 
be unique to ME/CFS is post-exertional malaise (PEM). 
PEM can be described as delayed and significant 
exacerbation of ME/CFS symptoms that always follow 
physical and cognitive activity [1]. 
Although ME/CFS and Long-haul COVID-19 are 
medically distinct, they share a common pathological 
process including viral infection, altered mitochondrial 
dynamics with sequent oxidative stress, pro-inflamma-
tory state, cytokine production, and cell death [3]. Acute 
Epstein-Barr virus (EBV) infection is an important virus 
trigger of ME/CFS. Some researchers speculate that 
SARS-CoV-2 could replace the EBV as being the most 
frequent precipitating event for ME/CFS or Long-haul 
COVID-19. Considering the overlapping of symptoms, 
ME/CFS and Long-haul COVID-19 should be better 
characterized as post active phase of infection syn-
dromes (PAPIS) [1].  Furthermore, the opportunities to 
learn about pathophysiology and treatments from the 
study of these commonalities and differences in each 
disease should be recognised.
PVFS may also result from immune system over-
reaction associated with ongoing production of in-
creased cytokine levels, especially interleukins 6 and 
10. These cytokines are also thought to play a key role 
in immune dysregulation and are frequently reported 
as abnormal in many cases of ME/CFS. In patients with 
Longhaul-19 symptoms lasting for more than 3 months 
with a functional impairment that prevents a return to 
everyday activities (education, employment) a diagnosis 
of ME/CFS should be considered. [2–3].
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Patient evidence also indicates that a good initial ap-
proach to the management of PVS reduces the probability 
of this turning into ME/CFS. The standard approach to the 
management of any form of significant post viral fatigue 
involves convalescence and a gradual return to normal 
daily activities. A recent study using an MRI scan showed 
cardiac inflammatory involvement in both hospitalised 
and non-hospitalised subgroups. Thus, proper evaluation 
of cardiac and respiratory function is needed [2]
This is an important time for those currently with, 
or at risk of postinfectious syndromes which includes 
some with ME/CFS.  Exploration of the causation and 
effective treatment of such syndromes will improve 
the understanding and treatment regardless of the 
triggering illness. Novel research into COVID-19 may 
lead to a much better understanding of the role of the 
immune response and why some people develop post 
viral syndromes and ME/CFS [1, 4].
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